Skip to Content

Taxotere (docetaxel) Disease Interactions

There are 5 disease interactions with Taxotere (docetaxel):

Major

Antineoplastics (Includes Taxotere) ↔ Infections

Severe Potential Hazard, High plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  3. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  4. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  5. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  6. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  7. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  8. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  9. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  10. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  11. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  12. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  13. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  14. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  15. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  16. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  17. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  18. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  19. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  20. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  21. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  22. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  23. "Product Information. Tabloid (thioguanine)." Glaxo Wellcome, Research Triangle Park, NC.
  24. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
  25. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  26. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  27. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  28. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  29. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.
  30. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  31. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.
View all 31 references
Major

Docetaxel (Includes Taxotere) ↔ Eye Disorder

Severe Potential Hazard, Moderate plausibility

Applies to: Macular Edema

Cystoid macular edema has been reported with the use of docetaxel. Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination prior to therapy with this agent. If cystoid macular edema is diagnosed, treatment should be discontinued and appropriate treatment initiated. Alternative non-taxane cancer treatment should be considered.

Major

Docetaxel (Includes Taxotere) ↔ Hepatic Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Docetaxel is extensively metabolized by the liver. Total body clearance of docetaxel has been reported to be reduced as much as 27% in patients with mild to moderate hepatic impairment resulting in a 38% increase of docetaxel serum concentration. Patients with elevated transaminase levels (>1.5 times the upper limits of normal) and alkaline phosphatase (>2.5 times the upper limits of normal) should not be administered docetaxel. The incidence of docetaxel related deaths is increased in patients with impaired hepatic function. Bilirubin, transaminase, and alkaline phosphatase levels should be obtained prior to each cycle of docetaxel therapy. Patients with combined abnormalities of transaminases and alkaline phosphatase should not be treated with this agent.

References

  1. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
Major

Docetaxel (Includes Taxotere) ↔ Myelosuppression

Severe Potential Hazard, High plausibility

Applies to: Fever, Bone Marrow Depression/Low Blood Counts

The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3. Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia. Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel. Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection. Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3. A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3). It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.

References

  1. Bissett D, Kaye SB "Taxol and taxotere--current status and future prospects." Eur J Cancer 29a (1993): 1228-31
  2. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  3. Ravdin PM, Valero V "Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer." Semin Oncol 22 (2 suppl) (1995): 17-21
Moderate

Docetaxel (Includes Taxotere) ↔ Alcoholism

Moderate Potential Hazard, Moderate plausibility

Applies to: Alcoholism

The alcohol content in a dose of docetaxel injection may affect the central nervous system. Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content. Close monitoring is recommended in alcoholic patients. Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.

Taxotere (docetaxel) drug Interactions

There are 409 drug interactions with Taxotere (docetaxel)

Taxotere (docetaxel) alcohol/food Interactions

There is 1 alcohol/food interaction with Taxotere (docetaxel)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide